M&A Activity Likely to Pick Up for Medical-Technology Firms
Becton Dickinson, Cardinal Health, and Abbott are all on track to make acquisitions.
Becton Dickinson, Cardinal Health, and Abbott are all on track to make acquisitions.
Julie Utterback: Medical-technology firms are dipping their toes back into M&A waters after a brief drought recently. In stark contrast to the first quarter when there was no issuance related to acquisitions in the entire healthcare industry as firms grappled with uncertainty around recent ACA repeal and replacement efforts, we expect significant acquisition-related debt issuance from med-tech firms in the next few quarters.
In the largest M&A event, BBB+ rated Becton Dickinson agreed to acquire A+ rated C.R. Bard for about $24 billion. Becton plans to borrow $10 billion to fund this transaction, which will push leverage up to the mid-4s from around 3 times recently. Because of this planned combination, which is expected to close this fall, ratings on both companies are Under Review Negative.
Cardinal Health recently agreed to acquire Medtronic's patient care, deep vein thrombosis, and nutritional insufficiency businesses for $6 billion. While we do not see this as a significant event for Medtronic, Cardinal's management team plans to issue $4.5 billion in new senior notes by the end of the summer to fund the combination. That should cause gross leverage to rise and remain above 2 times through 2020, or above its previous target in the mid to high-1s. With this plan, our A rating on Cardinal is Under Review Negative.
In mid-April, Abbott recommitted to acquiring point-of-care diagnostics firm Alere, and this transaction is now expected to close by the end of the third quarter. As we stated when we downgraded our rating on Abbott by two notches in March, its rating is BBB+ with or without Alere. So we see no major changes to our view of Abbott because of this pending merger.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.